{"nctId":"NCT01920711","briefTitle":"Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction","startDateStruct":{"date":"2014-07-18","type":"ACTUAL"},"conditions":["Heart Failure With Preserved Ejection Fraction"],"count":4822,"armGroups":[{"label":"LCZ696","type":"EXPERIMENTAL","interventionNames":["Drug: LCZ696"]},{"label":"Valsartan","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Valsartan"]}],"interventions":[{"name":"LCZ696","otherNames":[]},{"name":"Valsartan","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Left ventricular ejection fraction (LVEF) ≥45% by echo during screening epoch or within 6 months prior to study entry.\n* Symptom(s) of heart failure (HF) and requiring treatment with diuretic(s) for HF at least 30 days prior to study entry.\n* Current symptom(s) of HF (NYHA class II-IV)\n* Structural heart disease (left atrial enlargement or left ventricular hypertrophy) documented by echocardiogram.\n* Elevated NT-proBNP\n\nExclusion Criteria:\n\n* Any prior measurement of LVEF \\< 40%.\n* Acute coronary syndrome (including MI), cardiac surgery, other major CV surgery within 3 months , or urgent percutaneous coronary intervention within 3 months or and elective PCI within 30 days prior to entry.\n* Any clinical event within the 6 months prior to entry could have reduced the LVEF (e.g., MI, CABG), unless an echo measurement performed after the event confirms a LVEF ≥45%.\n* Current acute decompensated HF requiring therapy.\n* Patients who require treatment with 2 or more of the following: an angiotensin converting enzyme inhibitor (ACEI), an angiotensin receptor blocker (ARB) or a renin inhibitor.\n* Alternative reason for shortness of breath such as: significant pulmonary disease or severe COPD, hemoglobin (Hgb) \\<10 g/dl, or body mass index (BMI) \\> 40 kg/m2.\n* Systolic blood pressure (SBP) ≥ 180 mmHg at entry, or SBP \\>150 mmHg and \\<180 mmHg at entry unless the patient is receiving 3 or more antihypertensive drugs, or SBP \\< 110 mmHg at entry.\n\nOther protocol-defined inclusion/exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Cumulative Number of Primary Composite Events of Cardiovascular (CV) Death and Total (First and Recurrent) HF Hospitalizations.","description":"The primary objective of this study is to compare LCZ696 to valsartan in reducing the rate of the composite endpoint of CV death and total (first and recurrent) HF hospitalizations, in HF patients (New York Heart Association \\[NYHA\\] Class II-IV) with preserved ejection fraction (left ventricular ejection fraction \\[LVEF\\] ≥45%). The treatment arm with the lower rate of events will be deemed as having a successful response.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"894","spread":null},{"groupId":"OG001","value":"1009","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"690","spread":null},{"groupId":"OG001","value":"797","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"204","spread":null},{"groupId":"OG001","value":"212","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in the Clinical Summary Score From Baseline to Month 8 by Kansas City Cardiomyopathy Questionnaire (KCCQ)","description":"The KCCQ is a validated instrument for self-assessment of quality of life and health status in heart failure (HF) patients. The clinical summary score, which is derived from the physical limitations and heart failure (HF) symptoms domains of the KCCQ is a valid measure for assessing the patient's health aspects that may be influenced by CV medications. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. Evaluation of change from baseline to month 8 in KCCQ a most sensitive, specific, and responsive health-related quality of life measure for heart failure symptoms and physical limitations.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5073","spread":"0.3709"},{"groupId":"OG001","value":"-2.5338","spread":"0.3729"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Month 8 in New York Heart Association (NYHA) Functional Class","description":"Evaluation of change from baseline to Month 8 in NYHA functional class, a well established grading scale used to classify a heart failure's (HF) patients' level of functionality based on the signs and symptoms of HF exhibited by the patient.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"347","spread":null},{"groupId":"OG001","value":"289","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1767","spread":null},{"groupId":"OG001","value":"1792","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"202","spread":null},{"groupId":"OG001","value":"221","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants With First Occurrence of a Composite Renal Endpoint","description":"Analyis of composite renal endpoint defined as renal death, or reaching ESRD, or ≥50% decline in eGFR relative to baseline, using Cox's proportional hazards model.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"60","spread":null}]}]}]},{"type":"SECONDARY","title":"All-cause Mortality","description":"Analysis for all-cause mortality using Cox's proportional hazards model.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"342","spread":null},{"groupId":"OG001","value":"349","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1424,"n":2419},"commonTop":["Hypotension","Renal impairment","Hypertension","Hyperkalaemia","Urinary tract infection"]}}}